biostudies-literature00580Kane EVLeukaemia and Lymphoma ResearchLega Italiana per la Lotta Contro i Tumori and Italian Association for Research on CancerNational Research Council (CNR) Applied Project ‘Clinical Applications of Oncological Research’European CommunityItalian Association for Cancer ResearchNational Institute of HealthNational Cancer InstituteNCI NIH HHSMinistry of Education, Science, Sports, Culture and Technology of JapanCanadian Institutes for Health ResearchChan Sisters FoundationCanadian Cancer Society through the National Cancer Institute of Canada433-441https://www.ebi.ac.uk/biostudies/studies/S-EPMC3551484biostudies-literatureUnknown24(2)<h4>Background</h4>Non-Hodgkin lymphoma (NHL) subtypes, diffuse large B-cell (DLBCL) and follicular lymphoma (FL) have different sex ratios and are diagnosed at ages over 60 years; DLBCL is more common in men and diagnosed at older ages than FL, which occurs more among women. This analysis of postmenopausal women examines the relationship between postmenopausal hormone therapy and NHL.<h4>Design</h4>Self-reported use of postmenopausal hormone therapy from 2094 postmenopausal women with NHL and 2731 without were pooled across nine case-control studies (1983-2005) from North America, Europe and Japan. Study-specific odds ratios (OR) and 95% confidence intervals (CI) estimated using logistic regression were pooled using random-effects meta-analyses.<h4>Results</h4>Postmenopausal women who used hormone therapy were at decreased risk of NHL (pooled OR = 0.79, 95% CI 0.69-0.90). Risks were reduced when the age of starting was 50 years or older. There was no clear trend with number of years of use. Current users were at decreased risk while those stopping over 2 years before diagnosis were not. Having a hysterectomy or not did not affect the risk. Favourable effects were present for DLBCL (pooled OR = 0.66, 95% CI 0.54-0.80) and FL (pooled OR = 0.82, 95% CI 0.66-1.01).<h4>Conclusion</h4>Postmenopausal hormone therapy, particularly used close to menopause, is associated with a decreased risk of NHL.Annals of oncology : official journal of the European Society for Medical OncologyPostmenopausal hormone therapy and non-Hodgkin lymphoma: a pooled analysis of InterLymph case-control studies.PMC3551484CA62006CA150037CA50850CA89745R01 CA92153CA45614HERPACC2CA143947CA87014P50 CA97274CA92153La Vecchia CCerhan JRDal Maso LSpinelli JJSanjose SInterLymph ConsortiumMatsuo KZheng TKane EVRoman EZhang YHolly EACostas LWang SSKricker ABernstein LBracci PM58falsePostmenopausal hormone therapy and non-Hodgkin lymphoma: a pooled analysis of InterLymph case-control studies.<h4>Background</h4>Non-Hodgkin lymphoma (NHL) subtypes, diffuse large B-cell (DLBCL) and follicular lymphoma (FL) have different sex ratios and are diagnosed at ages over 60 years; DLBCL is more common in men and diagnosed at older ages than FL, which occurs more among women. This analysis of postmenopausal women examines the relationship between postmenopausal hormone therapy and NHL.<h4>Design</h4>Self-reported use of postmenopausal hormone therapy from 2094 postmenopausal women with NHL and 2731 without were pooled across nine case-control studies (1983-2005) from North America, Europe and Japan. Study-specific odds ratios (OR) and 95% confidence intervals (CI) estimated using logistic regression were pooled using random-effects meta-analyses.<h4>Results</h4>Postmenopausal women who used hormone therapy were at decreased risk of NHL (pooled OR = 0.79, 95% CI 0.69-0.90). Risks were reduced when the age of starting was 50 years or older. There was no clear trend with number of years of use. Current users were at decreased risk while those stopping over 2 years before diagnosis were not. Having a hysterectomy or not did not affect the risk. Favourable effects were present for DLBCL (pooled OR = 0.66, 95% CI 0.54-0.80) and FL (pooled OR = 0.82, 95% CI 0.66-1.01).<h4>Conclusion</h4>Postmenopausal hormone therapy, particularly used close to menopause, is associated with a decreased risk of NHL.2013-01-01T00:00:00Z2013 Feb2024-11-07T14:14:36.251Z2019-03-27T01:03:35ZS-EPMC35514842296799510.1093/annonc/mds340